Despite the limitations associated with the use of erlotinib as a comparator, docetaxel, a common second-line treatment for KRAS-mutant NSCLC, showed similar median OS (7.9 months) and PFS (2.8 months) (32) to what was observed with second- and third-line erlotinib treatment in the JUNIPER trial (OS, 7.8 months; PFS, 1.9 months) (17). Here, KRAS is linked to non-small cell lung carcinoma.